Clinical trial
Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration
NCT00362180 · Kastle Therapeutics, LLC, Industry · Completed
Key facts
| NCT number | NCT00362180 |
|---|---|
| Title | Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration |
| Official title | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Apolipoprotein B(ApoB) Reduction by ISIS 301012 on Liver Triglyceride Content in Subjects With Varying Degrees of Hyperlipidemia |
| Lead sponsor | Kastle Therapeutics, LLC, Industry |
| Collaborators | Ionis Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lipid Metabolism, Inborn Errors, Hyperlipidemias, Metabolic Diseases, Hypolipoproteinemia, Hypolipoproteinemias, Hypobetalipoproteinemias, Metabolism, Genetic Diseases, Inborn and 8 more |
| Intervention type | Drug |
| Interventions | mipomersen, Placebo |
| Enrollment | 38 |
| Start date | Jul 1, 2006 |
| Primary completion | Mar 1, 2010 |
| Completion | Sep 1, 2010 |
| First posted | Aug 9, 2006 |
| Last update posted | Oct 21, 2016 |
| Countries | Netherlands |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: